Login to Your Account



NewCo News: Living Up to its Acronym, ACT Nears Telatinib Phase III

By Tom Wall


Friday, May 13, 2011
The "ACT" in ACT Biotech Inc. stands for "accelerate cancer therapeutics" and the 3-year-old San Francisco-based company is living up to its acronym as it nears the start of a Phase III trial in the second half of this year of lead candidate telatinib in combination with chemotherapy for the first-line treatment of advanced stomach cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription